US DOJ to Streamline Merger Reviews, Targeting Top Competition Concerns Over Broad Probes

The Quick Take

• The US Department of Justice will streamline company merger reviews, focusing on top competition concerns rather than expansive probes
• The change moves away from broad fact-finding missions, potentially shortening M&A review timelines
• Deal-makers and private equity firms are likely to see faster regulatory clarity on pending and planned acquisitions

The United States Department of Justice announced a significant change to how it reviews corporate mergers, with the new approach focusing exclusively on the top competition concerns within a proposed deal rather than conducting expansive probes and wide-ranging fact-finding missions. This policy shift represents a meaningful recalibration of antitrust enforcement under the current administration, moving away from the broad investigative approach that had lengthened deal timelines in recent years. The change is likely to reduce regulatory drag on M&A activity, providing clearer timelines for deal teams and acquirers who have been operating under heightened antitrust uncertainty since 2021.

For financial markets, the DOJ's streamlining signals a more permissive M&A environment, particularly for large-cap deals in technology, healthcare, and financial services — sectors where prior regulatory expansiveness had materially suppressed deal activity. Investment banks with M&A advisory practices stand to benefit from accelerating deal flow. Private equity firms holding portfolio companies through long-duration monetisation cycles will find exit timing improved. However, the change does not affect Federal Trade Commission reviews, which operate under separate authority, nor international reviews by the EU's DG Competition or the UK's Competition and Markets Authority.

The practical test of this policy change will be the first major merger filed under the new regime — its treatment will reveal whether DOJ's streamlining translates into materially faster second requests and reduced consent decree requirements. Companies with deals currently in DOJ review should reassess their timeline assumptions, particularly if they had budgeted for prolonged investigations. The FTC's stance will be critical to watch, as a significant portion of tech and healthcare mergers are reviewed concurrently by both agencies, and a divergence between DOJ and FTC approaches could create new complexity.

Synthesized from 1 source.